Anti-Obesity Medications
Anti-obesity medications treat the biology behind hunger, fullness, and weight regulation. Before prescribing, we review your full health history and labs to make sure a medication is safe and a good fit for you. Every medication plan includes nutrition, activity, and behavior support.
We also prescribe naltrexone/bupropion, a daily oral medication that acts on the brain’s hunger and reward pathways. It can help with cravings and emotional eating.
A weekly GLP-1 receptor agonist that reduces hunger and helps you feel full sooner. It also lowers cardiovascular risk in people with heart disease.
Monthly fee includes visits and health coaching. Medication and lab costs vary with insurance coverage.
A weekly GIP/GLP-1 receptor agonist that acts on two appetite and blood sugar pathways. It is also used to treat obstructive sleep apnea in adults with obesity.
Monthly fee includes visits and health coaching. Medication and lab costs vary with insurance coverage.
A daily oral medication that reduces appetite and helps with cravings. It is not safe during pregnancy, and we review contraception with you before starting.
Monthly fee includes visits and health coaching. Medication and lab costs vary with insurance coverage.
New & Upcoming Medications
Obesity medicine is changing fast. Here’s what’s newly available, and what’s coming next.
Newly approved
Wegovy pill (oral semaglutide 25 mg): the first once-daily GLP-1 pill for weight management. In the OASIS 4 trial, people lost an average of about 16.6% of their body weight. It’s taken on an empty stomach, 30 minutes before eating.
Foundayo (orforglipron): a once-daily GLP-1 pill approved in April 2026, with no food or water restrictions. In the ATTAIN-1 trial, people on the highest dose lost an average of about 11 to 12%.
In the pipeline (not yet FDA-approved)
CagriSema (semaglutide plus cagrilintide, an amylin analog): a weekly injection that led to about 20% weight loss in clinical trials. It was submitted to the FDA in December 2025 and is under review.
Retatrutide: a weekly injection that acts on three hormone pathways (GIP, GLP-1, and glucagon). In the phase 3 TRIUMPH-1 trial, people lost an average of up to 25% at 80 weeks. Approval isn’t expected before 2027.
MariTide (maridebart cafraglutide): a once-monthly injection now in phase 3 trials, with up to about 20% weight loss at one year in earlier studies.
Amylin-based medicines: drugs like eloralintide and amycretin work through amylin, a different fullness hormone, and are now in phase 3 trials.
Survodutide: a weekly GLP-1 and glucagon medicine in phase 3 trials for obesity and fatty liver disease.
Results come from different studies and can’t be compared directly. Pipeline medicines are only available through clinical trials, so be cautious of anyone selling “research” versions online. Last updated October 2026.
Curious whether a new option could be right for you? We’ll talk through how it fits your health, goals, and insurance coverage.
